Efficacy of photodynamic therapy for treatment of basal cell carcinoma in organ transplant recipients

Collier, N.J.; Ali, Fahad; Lear, John T.

doi:10.1007/s10103-013-1454-7

Cited by 12 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further retrospective study found 77.4% clearance using two treatments of MAL-PDT, one week apart. No significant difference was found in recurrence rates of NMSC between OTRs and non-transplant recipients [81]. This was supported by a prospective study of superficial and nodular BCCs in 18 OTRs.…”

Section: Organ Transplant Recipientsmentioning

confidence: 90%

Photodynamic Therapy and Non-Melanoma Skin Cancer

Griffin

Lear

2016

Cancers

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most common malignancy among the Caucasian population. Photodynamic therapy (PDT) is gaining popularity for the treatment of basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). A topical or systemic exogenous photosensitiser, results in selective uptake by malignant cells. Protoporphyrin IX (PpIX) is produced then activated by the introduction of a light source. Daylight-mediated MAL (methyl aminolaevulinate) PDT for AKs has the advantage of decreased pain and better patient tolerance. PDT is an effective treatment for superficial BCC, BD and both individual and field treatment of AKs. Excellent cosmesis can be achieved with high patient satisfaction. Variable results have been reported for nodular BCC, with improved outcomes following pretreatment and repeated PDT cycles. The more aggressive basisquamous, morphoeic infiltrating subtypes of BCC and invasive squamous cell carcinoma (SCC) are not suitable for PDT. Prevention of “field cancerization” in organ transplant recipients on long-term immunosuppression and patients with Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a promising development. The optimisation of PDT techniques with improved photosensitiser delivery to target tissues, new generation photosensitisers and novel light sources may expand the future role of PDT in NMSC management.

show abstract

Section: Organ Transplant Recipientsmentioning

confidence: 90%

Photodynamic Therapy and Non-Melanoma Skin Cancer

Griffin

Lear

2016

Cancers

View full text Add to dashboard Cite

show abstract

“…Advantages of PDT include the good or even very good aesthetic outcome and the fact that it can be performed on an outpatient basis. Moreover, treating immunosuppressed patients is also possible . The most significant downside is the pain associated with the procedure.…”

Section: Topical Treatmentmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.

show abstract

“…BCCs are less frequently studied than SCC and its precursors in the SOTR literature due to the reversal of SCC to BCC ratio from 1:4 in immunocompetent to 3.8:1 in white renal transplant recipients; however, PDT appears to be a good option with 17/18 cleared in a SOTR cohort by Guleng and Helsing (E) which included four nodular lesions (all cleared). BCC recurrence rate after two MAL‐cPDT treatments 2 weeks apart was reported by Collier and colleagues as 22.6% in SOTR (mean time to recurrence 1.3 years) and 15.2% in immunocompetent patients (mean time to recurrence 1.4 years), a nonstatistically significant difference, in a 2015 report which reviewed 23 SOTR and 80 immunocompetent patients (C), with a mean follow‐up time of 3.5 years.…”

Section: Review Of Photodynamic Therapy Outcomes In Solid Organ Transmentioning

confidence: 93%

Photodynamic therapy: A targeted literature review focussing on outcomes and optimisation in solid organ transplant recipients

Lim

Gordon

2019

Aust J Dermatology

View full text Add to dashboard Cite

Squamous cell carcinoma incidence is 65-to 250fold in solid organ transplant recipients, BCC is 10fold and in Australia, rates of skin cancer in solid organ transplant recipients reach 70-82% prevalence within the first 20 years; hence, effective, evidence-based treatment of early and precancerous lesions is an essential tool in dermatological patient care. Photodynamic therapy is used to treat a range of conditions including actinic keratoses, squamous cell carcinoma in situ, superficial basal cell carcinoma and nodular basal cell carcinoma. A literature review was undertaken to examine the outcomes of photodynamic therapy in solid organ transplant recipients and methods of optimising outcomes in solid organ transplant recipients. Study sizes were small and protocols varied widely, so meta-analysis was not possible; however, photodynamic therapy appears to be an acceptable treatment for approved indications in solid organ transplant recipients in whom ongoing surveillance is maintained to ensure clearance and detect recurrence. Methods for improving efficacy were also reviewed for this population. Improved outcomes may be achieved by combining photodynamic therapy with other local methods such as 5-fluorouracil or ablative fractional laser.

show abstract

Efficacy of photodynamic therapy for treatment of basal cell carcinoma in organ transplant recipients

Cited by 12 publications

References 12 publications

Photodynamic Therapy and Non-Melanoma Skin Cancer

Photodynamic Therapy and Non-Melanoma Skin Cancer

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Photodynamic therapy: A targeted literature review focussing on outcomes and optimisation in solid organ transplant recipients

Contact Info

Product

Resources

About